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The prostate in ageing males is prone to benign and malignant
proliferative changes (Carter and Coffey, 1990). Indeed, cancer of
the prostate is the most prevalent malignancy and the second-
highest fatal neoplasm among Western males (Chung, 1995). The
mechanism of prostatic carcinogenesis and tumour development is
likely to involve a multistep progression from premalignant cells
to cancerous cells which proliferate and metastasize (Huggins and
Hodges, 1941). Initially, the growth and development of prostate
cancer appears to be androgen-dependent. Nearly all men with
metastatic prostate cancer, treated with surgical or chemical castra-
tion, have an initial beneficial response to androgen withdrawal,
which induces tumour regression by apoptosis. Although this
initial approach has significant palliative value, nearly all patients
relapse with a hormonally independent disease (Denmeade et al,
1996). This hormonally independent disease also becomes resis-
tant to additional therapies, such as chemotherapy (Yagoda and
Petrylak, 1992), and displays growth autonomy (Figueroa et al,
1995). In the normal prostatic epithelium, cell proliferation is
balanced by an equal rate of apoptotic cell death. In prostate
cancer, however, this fine balance is lost, causing increased
cellular mass and tumour progression (Denmeade et al, 1996).
Hence, an effective therapy for prostate cancer should redress the
imbalance in programmed cell death, which seems to be important
for disease progression.
The Fas (APO-1/CD95) receptor belongs to the nerve growth
factor/tumour necrosis factor (NGF/TNF) receptor family and medi-
ates apoptosis in a variety of cell types (Yonehara et al, 1989; Oehm
et al, 1992). Although Fas seems to be a key regulator of apoptosis,
the pathways through which this molecule exerts its actions and the
mechanisms which determine whether any given cell is sensitive or
resistant to Fas remain to be fully elucidated. It seems that there is
not a strict correlation between Fas and Fas ligand (FasL) expression
and sensitivity to Fas-mediated cytotoxicity. In fact, activation of the
Fas signalling pathway(s) in a variety of tumour cell lines and in
activated lymphocytes does not always trigger apoptosis (Owen-
Schaub et al, 1994). Caspases are thought to play a central role in
apoptosis and de-regulation of some caspases may contribute to the
development of some cancers. Furthermore, there is evidence that
caspase-dependent cleavage of specific proteins may abrogate
important survival pathways (Widmann et al, 1998). Importantly,
commitment to Fas-induced apoptosis was shown to require caspase
activity (Longthorne et al, 1997). Following Fas trimerization there
seems to be sequential activation of caspase-1 (ICE)- and caspase-3
(CPP32)-like proteases (Enari et al, 1996). The activated caspases
can then cleave various substrates, which include Poly(ADP-
Ribose) polymerase (PARP), Lamin, rho-GDI, Actin, Ras GTPase-
activating protein, Raf-1 and Akt-1, eventually resulting in
morphological changes to the cells and nuclei (Nagata, 1997;
Widmann et al, 1998).
Previous work from our laboratory has shown the importance of
reactive oxygen intermediates (ROI) during apoptosis in HL-60
and U937 leukaemic cell lines (McGowan et al, 1994). In partic-
ular, peroxide production has been reported in response to a variety
of inducers of apoptosis (Gorman et al, 1997b; McGowan et al,
1998). The production of peroxide after cytotoxic insult and the
ability of antioxidants to inhibit PARP cleavage and apoptosis,
suggest that early activation of caspases may act as a common
response to cytotoxic insult and that ROI may serve as common
mediators of cell death in leukaemic cell lines (McGowan et al,
1996). In contrast to a well-established role in chemotherapeutic
drug-induced apoptosis, the involvement of ROI in Fas-mediated
signal transduction pathway(s) is still controversial. Schulze-
Osthoff and colleagues (1994) have shown that neither inhibitors of
the mitochondrial respiratory chain nor antioxidants protected
murine fibrosarcoma cells from Fas-mediated cell death. In
contrast, ROI have been reported to be involved in Fas-mediated
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in neutrophils (Kasahara et al, 1997). In addition, Dobbelsteen and
co-workers (1996) have shown that Fas ligation results in a rapid
and specific efflux of glutathione (GSH). Severe depletion of GSH
will lower the reducing capacity of a cell, enhancing oxidative
stress independent of any increase in the production of ROI.
Furthermore, an oxidative stress due to elevated intracellular super-
oxide levels has been shown to block Fas-mediated apoptosis in
cells that were constitutively Fas-sensitive (Clément and
Stamenkovic, 1996). These studies suggest that an imbalance in
ROI levels may play a role in Fas-mediated apoptosis.
Due to the complexity of prostatic cancer, successful treatment
of the disease is likely to require a multimodality therapy involving
cytokines (immunotherapy), cytotoxic drugs (chemotherapy)
and/or hormonal ablation. The present study was designed to
examine possible ways of bypassing the resistance of prostate
cancer cell lines to Fas-mediated apoptosis and to further elucidate
the signalling pathways involved in Fas signal transduction.
MATERIALS AND METHODS
Reagents and cell lines
Prostate cancer cell lines LNCaP and DU145 were obtained from
American Type Culture Collection (Rockville, MD, USA).
Primary antibodies used in this study were anti-Fas IgM, clone Ch-
11 (Upstate Biotechnology, Waltham, MA, USA); anti-Fas IgG,
clone SM1/1 (Bender MedSystems, Heidelberg, Germany); anti-
FasL, N-20 (Santa Cruz, CA, USA); anti-PARP, 06-557-MN
(Upstate Biotechnology) and anti-b-actin (Sigma, Poole, UK). The
caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone (ZVAD) was purchased from Enzyme System Products
(Dublin, CA, USA). The fluorescent probes 2¢,7¢-dichloro-
fluorescin diacetate (DCFH-DA), dihydroethidium (DHE) and
5,5¢,6,6¢-tetrachloro-1,1¢,3,3¢-tetraethyl-benzimidazolylcarbocya-
nine iodide (JC-1) were obtained from Molecular Probes (Leiden,
The Netherlands). Cell culture reagents were purchased from
Gibco/BRL (Paisley, UK), protein gel electrophoresis reagents
from BioRad (Hertfordshire, UK), cytotoxic drugs, propidium
iodide (PI) and RNAase were from Sigma, and all other reagents
were obtained from BDH (Cork, Ireland).
Cell culture
Prostate cancer cells were cultured in RPMI-1640 medium
containing 5% (v/v) fetal calf serum, 2 mML -glutamine, supple-
mented with penicillin–streptomycin (10 IU ml21, 10 mg ml21) and
fungizone amphotericin B (2.5 mg ml21). Cells were grown at 378C
in a humidified 5% carbon dioxide atmosphere and were routinely
subcultured every 4 days. Cell density and viability were assessed
by trypan blue exclusion, using a haemocytometer.
Expression of Fas and FasL by flow cytometry
For FasL expression assessment, cells were fixed with PBS/p-
formaldehyde (1%, w/v, 30 min, room temperature) and permeabi-
lized with cold ethanol (70%, v/v, overnight, 2208C). Cells were
incubated with a rabbit anti-FasL (2 mg ml21, 1 h, 48C), followed
by the secondary antibody (fluorescence isothiocyanate-conju-
gated, 30 min, 48C). Cells were analysed on a FACScan (Becton
Dickinson, Mountain View, CA, USA), equipped with Cell Quest
software (Becton Dickinson). Fixation and permeabilization steps
were omitted when analysing cells for Fas expression (mouse anti-
Fas IgG used at 2 mg ml21).
Fas-induced cell death
Cells were plated in 24-well plates and treatment with anti-Fas IgM
(200 ng/ml) was carried out for 24 h. Whenever used, cytotoxic
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Figure 1 (A) Flow cytometric analysis of Fas and FasL in prostate cancer
cell lines. LNCaP and DU145 cells were stained with a FITC-conjugated
secondary antibody alone (intrinsic fluorescence control), (•); or with anti-Fas
or anti-FasL, followed by the relevant secondary FITC-conjugated antibody,
(l l). Data shown is representative of at least three independent experiments.
(B) Fas-Induced cell death in prostate cancer cell lines. Cells were incubated
with cyclohexamide (CHX, 0.25 mg ml21), anti-Fas IgM (200 ng ml21), or both
for 24 h, and apoptosis levels were assessed by morphological analysis as
described in Materials and Methods. The data (from three independent
microscopic fields) represents mean apoptosis6standard error of the mean
and results shown are representative of at least three independent
experimentsdrugs (100 ng ml21 actinomycin D, 100 ng ml21 camptothecin,
1.25 mg ml21 etoposide, 1 mg ml21 cis-platinum(II)diaminedichlo-
ride, 0.25 mg ml21 cyclohexamide), were added 5 min prior to anti-
Fas IgM. When required, ZVAD (50 mM) was added 5 min prior the
addition of cytotoxics.
Morphological analysis
Briefly, supernatants were transferred to labelled test tubes and
cells were washed once in HBSS. Cells in each well were then
trypsinized using Trypsin/EDTA (TE) for 10 min at 378C. TE was
neutralized with complete media and cells were transferred to the
appropriate test tube. Cells were then cytospun at 100 g
(500 rpm) for 2 min. Slides were stained using the Rapi-Diff II kit
(Langan Back Services, Ireland) and cell morphology was
assessed by light microscopy, using previously defined criteria
(Wyllie et al, 1980).
Cell cycle analysis
Freshly harvested cells (2.5 3 105 ml21) were fixed in ice-cold
ethanol (70%, v/v), on ice for 15 min. Ethanol was removed by
centrifugation (200 g 35 min) and cells were resuspended in 1 ml of
a PBS/PI (50 mg ml21) solution containing RNAase (0.5 mg ml21).
Following a 30 min incubation on ice, in the dark, cells were
analysed by flow cytometry in FL2-H, on a FACScan equipped with
Cell Quest software.
Western blot
Whole cell lysates were prepared by solubilizing ~106 cells in
20 ml of lysing buffer (10 mM Hepes/NaOH, pH 8.0; 150 mM
sodium chloride; 500 mM sucrose; 1 mM EDTA; 0.15 mM sper-
mine; 1.0% v/v Triton X-100; 0.2 mM phenylmethylsulphonyl
fluoride; 1.0 mg ml21 antipain; 1.0 mgm l 21 aprotinin; 1.0 mgm l 21
chymostatin; 0.1 mg ml21 leupeptin; 4.0 mg ml21 pepstatin) and
incubating cells on ice for 1 h. Prior to electrophoresis, cells were
diluted in 23 sodium dodecyl sulphate (SDS) gel-loading buffer
(100 mM Tris–HCl, pH 6.8; 200 mM dithiothreitol; 4.0% w/v SDS;
0.2% w/v bromophenol blue; 20% v/v glycerol) and boiled for
15 min. Proteins were separated in a 10% (w/v) polyacrylamide
gel and blotted onto Trans-Blot nitrocellulose membrane. After
blocking, the membrane was incubated with anti-human PARP
(1/500 dilution, 48C, overnight), followed by an anti-rabbit-HRP-
conjugated antibody (1/1000, 1 h, room temperature). The
membrane was probed with ECL (Amersham) and exposed to
Kodak X-OMAT LS film (Sigma).
Detection of intracellular ROI and measurement of
mitochondrial transmembrane potential (Dym)
Mitochondrial membrane depolarization, peroxide and superoxide
levels were measured as previously described (Gorman et al,
1997a; Costa-Pereira and Cotter, 1999). Briefly, cells (2.5 3 105)
were harvested and incubated with 5 mg ml21 JC-1 (Dym measure-
ment), for 15 min; or with 5 mM DCFH-DA (peroxide level) for 1 h
at 378C; or with 5 mM DHE (superoxide anion) for 30 min at 378C.
Fluorescence due to JC-1 and oxidized DCFH-DA was measured
on a FACScan (Becton Dickinson, Mountain View, CA, USA),
equipped with Cell Quest software (Becton Dickinson), in FL-1,
whereas the fluorescence due to oxidation of DHE was measured
in FL-2. Cells were treated with the apoptosis-inducing agents
either before or during the incubation period, depending on the
time point at which ROI or Dym were to be studied.
RESULTS
Prostate cancer cells are resistant to Fas-mediated
cytotoxicity
Fas and FasL expression were assessed in LNCaP and in DU145
prostate cancer cells by flow cytometry (Figure 1A). Although
both cell lines expressed the ligand and the receptor, treatment of
cells with anti-Fas IgM (200 ng ml21; 24 h) induced only moderate
levels of apoptosis in the androgen-responsive cell line, LNCaP,
having no significant cytotoxic effects on the androgen-indepen-
dent cell line, DU145 (Figure 1B). LNCaP (but not DU145) cells
were more susceptible to Fas-mediated apoptosis when treated
concomitantly with anti-Fas and cyclohexamide (CHX, 0.25 mg
ml21), suggesting the presence of an endogenous protein inhibitor
of the Fas signalling pathway in these cells. These results are in
contrast to an article by Rokhlin et al (1997). However, their
DU145 were only susceptible to treatment with 1 mg ml21 anti-Fas
at high concentrations of CHX (2.5–25 mg ml21), and the resis-
tance displayed by their LNCaP cells is uncharacteristic of our cell
lines. The sensitization of LNCaP cells mediated by CHX was not
due to up-regulation of Fas, as assessed by flow cytometry (results
not shown). Dose–response curves for both LNCaP and DU145
cell lines treated with anti-Fas IgM showed that, even at high anti-
Fas IgM concentrations (1.5 mg ml21), DU145 cells were resistant
to anti-Fas-induced apoptosis, indicating that there is a bona fide
blockage in the Fas apoptotic pathway(s) in these cells. LNCaP
cells were more susceptible to anti-Fas and there was, to a certain
extent, a dependency on the dose of antibody used. The apoptosis
levels, however, never surpassed those observed when LNCaP
cells were treated with 0.25 mg ml21 CHX (data not shown).
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Figure 2 Chemosensitization of androgen-independent prostate cancer
cells to Fas-induced cell death. DU145 cells were treated with subtoxic doses
of camptothecin (100 ng ml21) and concomitantly incubated with anti-Fas IgM
(200 ng ml21), for 24 h. Apoptosis was assessed as described in Figure 1BSensitization of androgen-independent prostate cancer
cells to anti-Fas-induced cell death
To address the possible mechanism(s) involved in the resistance
displayed by prostate cancer cells to Fas-induced apoptosis, we
have used a number of cytotoxic drugs known to have distinct
intracellular targets. The chemotherapeutic drugs used were:
actinomycin D (RNA transcription inhibitor, which can also
induce topoisomerase I and II cleavable complexes), camptothecin
(topoisomerase I inhibitor), cis-platinum(II)diamminedichloride
(CPDD) (non-classical alkylating agent, which forms intrastrands
linkages with DNA) and etoposide (topoisomerase II inhibitor).
DU145 were sensitized by ~20-fold (average of five independent
experiments yielding similar results) when treated with subtoxic
concentrations of camptothecin (100 ng ml21) and subsequently
treated with anti-Fas IgM (200 ng ml21) (Figure 2). The sensitiza-
tion does not seem to be particular to topoisomerase I inhibitors, as
actinomycin D (100 ng ml21), CPDD (1.0 mg ml21) and etoposide
(1.25 mg ml21) also sensitized DU145, although to a lesser extent
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Figure 3 Fas and FasL expression in untreated DU145 cells and in cells treated with camptothecin (100 ng ml21). DU145 cells were stained with a FITC-
conjugated secondary antibody alone (intrinsic fluorescence control), (•); or with anti-Fas or anti-FasL, followed by the relevant secondary FITC-conjugated
antibody, (l l). Data are for the 24 h time point and are similar to those seen for the 4 and 8 h points
Figure 4 Cell cycle analysis of untreated DU145 cells and cells treated with anti-Fas (200 ng ml21), camptothecin (100 ng ml21), or both, at the indicated times.






















T24(data not shown). Identical concentrations of actinomycin D,
camptothecin, or etoposide failed to sensitize the androgen-
responsive cells, LNCaP (not shown).
Camptothecin-mediated sensitization of DU145 cells
to anti-Fas-induced cell death does not involve
up-regulation of Fas or FasL proteins
Recent reports (Friesen et al, 1996; Herr et al, 1997) suggested that
apoptosis caused by certain anticancer drugs was mediated by the
Fas/FasL system. In order to determine whether camptothecin was
sensitizing DU145 cells to Fas-mediated apoptosis by up-regu-
lating Fas and/or FasL, cells were treated with camptothecin and
flow cytometric analysis of Fas and FasL expression was assessed
at different time points (4 and 24h post-treatment). Results show
that there was no change, at the protein level, of Fas or FasL
(Figure 3), suggesting that sensitization was not due to upregula-
tion of Fas and/or FasL.
Camptothecin’s effect is independent of alterations in
the cell cycle
Camptothecin has been reported to cause a cell cycle arrest in
S/G2 (Hsiang et al, 1989). Thus it was considered that the sensiti-
zation to Fas-mediated apoptosis could be a consequence of cell
cycle arrest. Flow cytometric analysis of untreated cells, or cells
treated with camptothecin (100ng ml21), anti-Fas IgM
(200ng ml21), or camptothecin plus anti-Fas, for 8h, showed no
significant cell cycle abnormalities in the cell cycle profile of each
sample. After a 24h treatment with camptothecin plus anti-Fas
IgM, only sub-G0/G1 population was slightly increased indicative
of apoptosis (Figure 4).
Activation of caspases is required for camptothecin-
mediated sensitization of DU145 cells to anti-Fas-
induced apoptosis
There have been several reports showing that caspases play a
pivotal role in Fas-induced apoptosis (Enari et al, 1996;
Longthorne and Williams, 1997). Western blot analysis demon-
strated that poly(ADP-ribose) polymerase was proteolytically
cleaved in camptothecin-treated cells, but not in cells treated with
anti-Fas only (Figure 5A). A down-regulation of PARP, in the
absence of cleavage product, was noted in cells treated with camp-
tothecin only. This may be due to an inhibition of transcription.
Apoptosis in cells treated with camptothecin plus anti-Fas could be
completely blocked by pretreatment with ZVAD (50mM) (Figure
5B). Thus, camptothecin sensitization involves the activation of
caspases analogous to apoptosis in Fas-sensitive cells.
Mitochondrial depolarization is a late and non-specific
event in DU145 cells undergoing camptothecin-
mediated anti-Fas-induced apoptosis
Emerging evidence suggests a key role for mitochondria during
apoptosis induced by a diverse range of stimuli. Discontinuity of
the outer mitochondrial membrane results, in some instances, in
redistribution of cytochrome cfrom the intermembrane space to the
cytosol, followed by subsequent inner mitochondrial membrane
depolarization (Kroemer, 1997). Disruption of the transmembrane
potential (Dym) and generation of reactive oxygen intermediates
(ROI) have been reported as early events in apoptosis (Lennon et al,
1991; Kroemer, 1997). Dym depolarization was only significant
(but not complete) at 24h, when .80% of cells were dead (Figure
6). Dym disruption was evidently a late event in our system. Taken
together, results suggest that, although degradation of Dym might
contribute to the apoptosis of DU145 cells, it is unlikely that camp-
tothecin causes sensitization to anti-Fas through this mechanism.
Camptothecin opens the Fas apoptotic pathway(s) in
DU145 cells through an ROI-independent mechanism
Apoptotic cells are believed to be subject to some form of oxidative
stress, as they accumulate oxidized proteins and lipids (Buttke and
Sandstrom, 1994) and, in a number of cell lines, apoptosis induced
by chemotherapeutic drugs is accompanied by rapid production of
ROI (Lennon et al, 1991; McGowan et al, 1996; Gorman et al,
1997b). Furthermore, Fas-mediated cell death has been shown to be
blocked by superoxide anion (Clément and Stamenkovic, 1996),
suggesting that an imbalance in ROI levels may have a role to play
in Fas-mediated cell death. The existence of a short-lived inhibitor
protein of Fas signalling transduction pathway(s) has been widely
suggested. However, since the protein synthesis inhibitor cyclo-
hexamide did not sensitize DU145 cells to anti-Fas-mediated apop-
tosis, we sought to investigate alternative mechanism(s) which did
not directly involve proteins. We hypothesized that camptothecin
could be opening the Fas pathway in DU145 cells by either
Camptothecin-mediated Fas-induced apoptosis375
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Figure 5(A) Caspases are involved in camptothecin-mediated anti-Fas-
induced apoptosis of DU145 cells. Western blot analysis of PARP cleavage
in untreated (lane 1) DU145 cells, or treated with anti-Fas IgM, 200ng ml21
(lane 2); Camp, 100ng ml21 (lane 3); Camp. and anti-Fas (lane 4). The
membrane was also probed with anti-b-actin to ensure equal protein loading
(30mg protein/lane). (B) Inhibition of Fas-induced apoptosis in DU145
cells pretreated with camptothecin by a caspase inhibitor, ZVAD. Cells
(5 3104 ml21) were seeded in 24-well plates and cultured for 48h. Cells
were incubated for 5min with 50mMof ZVAD, followed by treatment with
camptothecin (100ng ml21), anti-Fas IgM (200ng ml21), or both, for 24h.
Apoptosis levels were assessed as described in Figure 1B
A
Bincreasing peroxide levels (Figure 7A) or by directly or indirectly
causing a fall in superoxide levels (Figure 7B). None of the treat-
ment (anti-Fas, camptothecin, camptothecin plus anti-Fas), under
our experimental conditions, caused a significant increase in
peroxide or a decrease in superoxide anion levels, as measured
by flow cytometry. Camptothecin, at higher concentrations (1–
10 mg ml21), did cause a rapid and marked increase in ROI levels
(results not shown), but not at the concentrations used here (100 ng
ml21, 24 h treatment). While it is possible that an alternative mech-
anism of oxidative stress contributes to camptothecin and anti-Fas
cytotoxicities, the data presented in this study suggest that ROI are
not significant players in camptothecin-mediated sensitization of
DU145 cells to anti-Fas-induced apoptosis.
DISCUSSION
Although prostate cancer cells expressed both Fas and FasL, they
were significantly resistant to Fas-induced cell death. This obser-
vation, and the fact that the Fas/FasL system is emerging as one of
the key apoptotic pathways in eukaryotic cells, prompted us to
investigate why Fas-mediated apoptotic pathway(s) were blocked
in these cells. Understanding the mechanisms underlying this
resistance may allow the development of strategies for effectively
killing prostate cancer cells, using a combination of cytotoxic and
immune approaches. In this study, two prostate cancer cell lines
(LNCaP, DU145) were used. It was shown that LNCaP and
DU145 cells expressed both Fas and FasL. Treatment of LNCaP
and DU145 with anti-Fas IgM and CHX up to 24 h induced
moderate levels of apoptosis in LNCaP, having no significant cyto-
toxic effects on DU145 cells. LNCaP were more susceptible to
anti-Fas when pretreated with CHX, suggesting that there might be
a short-lived inhibitor in these cells. The existence of a hypothet-
ical suppressor of Fas-induced apoptosis (‘Saf’ – suppressor of
apoptosis by Fas) has been postulated (Green, 1997). Such
suppressor is likely to exist, as in many cells resistance to Fas can
be overcome by treatment with cyclohexamide or actinomycin D,
which are thought to eliminate such short-lived inhibitor. FLIP (for
Flice inhibitory protein), a molecule recently identified by Irmler
and co-workers (1997), seems to be an appropriate candidate for
such a role. A number of cytotoxic drugs were shown to sensitize
androgen-independent cells (DU145) to anti-Fas-induced apop-
tosis. Indeed, DU145 cells were sensitized by ~20-fold when
treated with subtoxic doses of camptothecin and concomitantly
incubated with anti-Fas. This sensitization was not particular to
topoisomerase I inhibitors, as actinomycin D, CPDD and etopo-
side also sensitized cells to cell death. Interestingly, we were
unable to chemosensitize the androgen-responsive cells (LNCaP)
using the above mentioned cytotoxic drugs.
It has been postulated that chemotherapeutic drugs induced
apoptosis by activating the Fas/FasL apoptotic pathway (Friesen et
al, 1996; Müller et al, 1997). There is an accumulating body of
evidence which suggests that this is not always the case (Eischen et
al, 1997; Villunger et al, 1997; McGahon et al, 1998). It has been
suggested that lack of p53 expression might account for the lack of
recruitment of Fas and FasL (Müller et al, 1997). Treatment of
DU145 cells with camptothecin did not alter the levels of Fas, or
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Figure 6 Mitochondria transmembrane potential disruption in DU145 cells. In cells treated with camptothecin (100 ng ml21), anti-Fas IgM (200 ng ml21), or
both, Dym depolarization is a late event and does not correlate with apoptosis levels. FL-2H fluorescence of cells treated with camptothecin, anti-Fas, or both
remained unchanged and was identical to the FL-2H of untreated cells. Dym was measured by flow cytometry as described in Materials and Methods. Data are
for the 24 h time point and are representative of three independent experimentsFasL, as shown by flow cytometry. DU145 cells have been shown
to possess a mutated p53 (Isaacs et al, 1991), which further
suggests that DU145 cells might be unable to up-regulate Fas or
FasL proteins. In addition, cell cycle analysis of cells treated with
anti-Fas, camptothecin, or camptothecin plus anti-Fas, has shown
that camptothecin was mediating Fas-induced cell death through a
mechanism which was independent of cell cycle alterations.
Camptothecin has been shown to induce single-strand DNA breaks
in the presence of topoisomerase I, which is a major target for the
anti-tumour effect (Hsiang et al, 1989). How this is translated into a
cytotoxic effect is, however, currently unknown.
Camptothecin sensitization was shown to involve activation of
caspases analogous to apoptosis in Fas-sensitive cells. Indeed,
poly(ADP-ribose) polymerase was proteolytically cleaved in cells
treated with camptothecin plus anti-Fas, but not in cells treated
with anti-Fas only. Furthermore, camptothecin-mediated sensitiza-
tion of DU145 cells to Fas-induced apoptosis was completely
blocked by the caspase inhibitor ZVAD.
A variety of stimuli have been shown to cause an accumulation
of cytochrome c in the cytosol, cause disruption of mitochondria
transmembrane potential and an increase in ROI, leading to activa-
tion of caspases, PARP cleavage, DNA degradation and subse-
quent apoptosis. We hypothesized that camptothecin could be
sensitizing DU145 cells to anti-Fas-induced apoptosis through an
ROI-mediated mechanism. Results, however, seem to negate this
hypothesis: (1) an increase in peroxide, which is thought to induce
apoptosis by increasing cellular oxidative stress beyond the toler-
able threshold, could not be detected; (2) no decrease in super-
oxide anion was observed.
In summary, our results show that a combinatory treatment of
androgen-independent DU145 cells with sublethal concentrations
of camptothecin and very low concentrations of anti-Fas IgM, will
kill nearly all cells (75–95%) in 24 h. The mechanism of this coop-
eration appears to be independent of alterations in the levels ROI
(peroxide and superoxide anion). Because we were able to
chemosensitize the androgen-independent cells (DU145), but not
Camptothecin-mediated Fas-induced apoptosis 377























































Figure 7 (A) Camptothecin-mediated anti-Fas-induced apoptosis is independent of production of peroxide. Cells were treated with camptothecin (100 ng ml21),
anti-Fas IgM (200 ng ml21), or both, and peroxide levels were assessed, as described in Materials and Methods. Data shown are for the 4, 8 and 24 h time point
and are similar to those seen for earlier time points (0.5, 1 and 2 h). Data shown is representative of three independent experiments. (B) Levels of superoxide
anion remained unaltered in DU145 cells undergoing camptothecin-mediated anti-Fas-induced apoptosis. Cells were treated with camptothecin (100 ng ml21),
anti-Fas IgM (200 ng ml21), or both, and superoxide anion was as described in Materials and Methods. Data shown are for the 4, 8 and 24 h time points and are
similar to those seen for 0.5, 1 and 2 h time points. Data shown is representative of three independent experimentsthe androgen-responsive cells (LNCaP), it is tempting to speculate
that the resistance of a prostate cell line to anti-Fas IgM treatment
may be inversely proportional to its positive response to chemosen-
sitization. This would have important implications for therapy
since, although nearly all men with metastatic prostate cancer
respond well initially to some sort of hormonal ablation therapy,
prostate cancer cells invariably become androgen-independent.
This is invariably fatal because no effective systemic therapy
currently exists. Taken together, these results seem to indicate that a
combination of chemotherapy and immunotherapy may present a
novel approach for the elimination of androgen-independent cells.
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